Ensysce Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on April 7, 2026, regarding events occurring on April 6, 2026. Ensysce Biosciences, Inc. (Nasdaq: ENSC), a biopharmaceutical company, reported the closing of a private placement offering pursuant to a Securities Purchase Agreement originally entered into on November 13, 2025.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $2.0 million.
- Estimated Net Proceeds: Approximately $1.9 million.
- Securities Issued:
- 2,000 shares of Series B Preferred Stock (par value $0.0001).
- Up to 4,363,636 shares of Common Stock issuable upon conversion of Preferred Stock.
- Warrants to purchase up to 8,727,273 shares of Common Stock.
- Warrants to purchase up to 261,818 shares of Common Stock issued to financial advisor designees.
- Conversion/Exercise Price: $0.55 per share (subject to adjustment).
- Preferred Stock Stated Value: Amended from $1,100 to $1,200 per share.
- Warrant Terms:
- 4,363,637 warrants exercisable for 18 months.
- 4,363,636 warrants exercisable for five years.
- Includes anti-dilution provisions and cash-out provisions in change of control scenarios.
Note: The filing does not provide specific data on revenue, operating profit, cash flow, margins, or total debt levels as of the reporting date.
Material Changes and Covenants
The transaction represents a material change in the company's capital structure. Key terms include:
- Registration Rights: The Company agreed to file a registration statement for the resale of shares within three business days of the closing date.
- Beneficial Ownership Limitation: Warrant holders cannot exercise if it results in beneficial ownership exceeding 4.99% (or 9.99% at election), subject to notice provisions.
- Lock-up on Issuances: The Company is restricted from issuing Common Stock or equivalents, filing registration statements (with exceptions), or entering into "Variable Rate Transactions" while the Purchaser holds Preferred Stock with an aggregate stated value of $100,000.
- Price Adjustments: The Conversion Price and Exercise Price are subject to downward adjustment if the Company issues equity at a price lower than the current price.
Outlook, Use of Proceeds, and Risks
Use of Proceeds: The Company intends to use the net proceeds for general corporate purposes, specifically the continued development of its TAAP and MPAR® programs, and for working capital.
Risks and Contingencies:
- The securities were sold under Section 4(a)(2) and Rule 506(b) exemptions and are not registered with the SEC.
- Forward-looking statements regarding the use of proceeds and program development are subject to risks and uncertainties that may cause actual results to differ materially.
- The agreement contains complex anti-dilution and price adjustment mechanisms that could significantly impact future share counts and valuation.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-closing to assess the dilution impact of the 4.36 million convertible shares and 8.73 million warrant shares.
- Review the "Variable Rate Transaction" definition to understand restrictions on future capital raises.
- Confirm the status of the registration statement filing for the resale of securities (required within 3 business days of April 6, 2026).
- Monitor the Company's cash runway relative to the $1.9 million net proceeds and ongoing development costs for TAAP and MPAR® programs.
- Check for any subsequent filings regarding further adjustments to the $0.55 exercise/conversion price.